Clover Health Investments, Corp. (CLOV) fair value analysis
Nasdaq · Updated 2026-10-19
CLOV price how computed
Valuation status
Awaiting full valuationCLOV's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once CLOV's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $4.48
- Sector
- Healthcare
- 12-month range
- $1.70–$5.41
- Market cap
- $2.38B
- From 52-week high
- -17.2%
- Shares outstanding
- 531M
- Rank in Healthcare by quality score
- #148 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Clover Health Investments, Corp. is a healthcare company that provides Medicare Advantage insurance plans to seniors. The company operates primarily in the United States, offering coverage and related services to eligible beneficiaries across multiple states.
CLOV currently ranks #148 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.38B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $2.48B
- Net margin
- -0.7%
- EPS (TTM)
- $-0.02
- Gross margin
- 20.6%
- Revenue growth (3-yr avg)
- 47.6%
- Shares outstanding
- 531M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 45 · neutral
- 50-day average
- $4.46
- 200-day average
- $3.44
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-04 (post-market)
- Last 8 quarters vs consensus
- 5 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+20.0%)
2026-03 ▬ met (0.0%)
2025-12 ▲ beat (+9.1%)
2025-09 ▼ miss (-350.0%)
2025-06 ▬ met (0.0%)
2025-03 ▲ beat (+171.4%)
2024-12 ▲ beat (+23.1%)
2024-09 ▲ beat (+33.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 1 buy · 2 hold · 0 sell (3 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $5.38
- Target vs last price
- +20.1%
What our data shows for CLOV
- Shares are trading in the upper third of their 12-month price range of $1.70–$5.41.
- The 14-day relative strength index sits at a neutral 45.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- CLOV's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent CLOV news
TickrTrends' derived news-sentiment signal for CLOV is currently leaning positive, computed from recent coverage.
- Clover Health (CLOV) CEO Jamie Reynoso Sells 4,066 Shares (gurufocus.com, 2026-10-20)
- Clover Health Earns Top Honors in U.S. News & World Report's 2027 Medicare Advantage Ratings Across Three States (manilatimes.net, 2026-10-19)
- Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027 (manilatimes.net, 2026-10-08)
More CLOV news
- UPDATE - Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors (manilatimes.net, 2026-09-24)
- Clover Health (CLOV) CEO Jamie Reynoso Sells 1,921 Shares as Stock Trades Near GF Value (gurufocus.com, 2026-09-18)
What people are saying
Follow the CLOV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CLOV stock undervalued?
CLOV's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is CLOV's TickrTrends verdict?
CLOV is currently marked 'Awaiting full valuation' - a verdict publishes automatically once CLOV's own trailing P/E history validates under our standards.
How does CLOV compare to other Healthcare stocks?
CLOV ranks #148 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is CLOV overbought or oversold?
CLOV's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does CLOV report earnings next?
CLOV's next earnings report is scheduled for 2026-11-04 (post-market), per the published earnings calendar.
Does CLOV usually beat earnings estimates?
Over its last 8 reported quarters CLOV beat the consensus estimate 5 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CLOV?
Of 3 analysts covering CLOV, 1 rate it a buy, 2 a hold and 0 a sell - hold-leaning, with a consensus price target of $5.38 (+20.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.